Oryzon Genomics - New clinical candidate expands CNS portfolio
Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders...
215 Views
Oryzon Genomics - Catalysts on the horizon in FY23
FY23 is shaping up to be a busy clinical year for Oryzon with readouts and trial initiations expected across its lead assets. The next major...
231 Views
Oryzon Genomics - KOL event puts near-term catalysts in the spotlight
At Oryzon’s recent key opinion leader (KOL) event, management elaborated on the near-term clinical catalysts for its lead assets iadademstat, in...
187 Views
Oryzon Genomics - Progress in oncology and CNS in FY22
Oryzon Genomics has presented headline FY22 financial results, which reflect continued progress on its clinical activities for key assets...
204 Views
Oryzon Genomics - First Phase II patient enrolled is clinical milestone
Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1...
190 Views